Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT05440786
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸The Regents of the University of California - Los Angeles (UCLA Pediatrics), Los Angeles, California, United States
🇺🇸Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT05440136
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT05440344
- Locations
- 🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation at Texas Liver Institute, San Antonio, Texas, United States
A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 25
- Registration Number
- NCT05436912
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Orange County Research Institute, Anaheim, California, United States
🇺🇸Riverside Clinical Research, Edgewater, Florida, United States
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 780
- Registration Number
- NCT05433584
- Locations
- 🇺🇸
New England Research Associates, LLC, Bridgeport, Connecticut, United States
🇺🇸Velocity Clinical Research, San Diego, La Mesa, California, United States
🇺🇸Research Foundation of SUNY - University of Buffalo, Buffalo, New York, United States
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 469
- Registration Number
- NCT05412004
- Locations
- 🇺🇸
NeuroScience Research Center, Canton, Ohio, United States
🇧🇷BR Trials - Ensaios Clinicos e Consultoria, São Paulo, Brazil
🇩🇪InnoDiab Forschung Gmbh, Essen, Nordrhein-Westfalen, Germany
A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT05407961
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Germany
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 176
- Registration Number
- NCT05395481
- Locations
- 🇺🇸
Advanced Pharma Clinical Research, Miami, Florida, United States
🇺🇸IU Health University Hospital, Indianapolis, Indiana, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
A Study of LY3541105 in Healthy and Overweight Participants
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 205
- Registration Number
- NCT05380323
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
🇺🇸PRA International, Lenexa, Kansas, United States
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 94
- Registration Number
- NCT05377333
- Locations
- 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸CenExel-HRI, Berlin, New Jersey, United States
🇺🇸Pinnacle Research Group, LLC, Anniston, Alabama, United States